BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36440187)

  • 21. Clinical, Diagnostic, and Treatment Characteristics of
    Jha A; de Luna K; Balili CA; Millo C; Paraiso CA; Ling A; Gonzales MK; Viana B; Alrezk R; Adams KT; Tena I; Chen A; Neuzil J; Raygada M; Kebebew E; Taieb D; O'Dorisio MS; O'Dorisio T; Civelek AC; Stratakis CA; Mercado-Asis L; Pacak K
    Front Oncol; 2019; 9():53. PubMed ID: 30854332
    [No Abstract]   [Full Text] [Related]  

  • 22.
    Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of [68Ga]DOTANOC PET/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study.
    Singh D; Shukla J; Walia R; Vatsa R; Paul N; Chhabra A; Nahar U; Singh H; Kumar R; Bhansali A; Rai Mittal B
    Nucl Med Commun; 2020 Oct; 41(10):1047-1059. PubMed ID: 32732602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
    Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
    Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.
    Sait S; Pandit-Taskar N; Modak S
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28409892
    [No Abstract]   [Full Text] [Related]  

  • 26. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
    Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma.
    Jafri M; Whitworth J; Rattenberry E; Vialard L; Kilby G; Kumar AV; Izatt L; Lalloo F; Brennan P; Cook J; Morrison PJ; Canham N; Armstrong R; Brewer C; Tomkins S; Donaldson A; Barwell J; Cole TR; Atkinson AB; Aylwin S; Ball SG; Srirangalingam U; Chew SL; Evans DG; Hodgson SV; Irving R; Woodward E; Macdonald F; Maher ER
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):898-906. PubMed ID: 23072324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
    Kornaczewski ER; Pointon OP; Burgess JR
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel SDHB c.563 T > C mutation responsible for Paraganglioma syndrome and genetic analysis of the SDHB gene in China: a case report.
    Chen H; Yao W; He Q; Yu X; Bian B
    BMC Med Genet; 2020 May; 21(1):116. PubMed ID: 32460727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model systems in SDHx-related pheochromocytoma/paraganglioma.
    Takács-Vellai K; Farkas Z; Ősz F; Stewart GW
    Cancer Metastasis Rev; 2021 Dec; 40(4):1177-1201. PubMed ID: 34957538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
    Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
    Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.
    Kong G; Schenberg T; Yates CJ; Trainer A; Sachithanandan N; Iravani A; Ravi Kumar A; Hofman MS; Akhurst T; Michael M; Hicks RJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5091-5099. PubMed ID: 30977831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
    King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
    J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Krokhmal AA; Kwatra N; Drubach L; Weldon CB; Janeway KA; DuBois SG; Kamihara J; Voss SD
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29740. PubMed ID: 35484995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
    Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
    Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
    Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
    Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.
    Astuti D; Hart-Holden N; Latif F; Lalloo F; Black GC; Lim C; Moran A; Grossman AB; Hodgson SV; Freemont A; Ramsden R; Eng C; Evans DG; Maher ER
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):728-33. PubMed ID: 14974914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: A pilot study.
    Tufton N; White G; Drake WM; Sahdev A; Akker SA
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):104-109. PubMed ID: 30934121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.